Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Equity Ratio (2016 - 2020)

Historic Equity Ratio for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to 0.9.

  • Larimar Therapeutics' Equity Ratio rose 3971.82% to 0.9 in Q3 2020 from the same period last year, while for Sep 2020 it was 0.9, marking a year-over-year increase of 3971.82%. This contributed to the annual value of 0.13 for FY2019, which is 11741.96% down from last year.
  • As of Q3 2020, Larimar Therapeutics' Equity Ratio stood at 0.9, which was up 3971.82% from 0.9 recorded in Q2 2020.
  • Larimar Therapeutics' 5-year Equity Ratio high stood at 0.93 for Q1 2017, and its period low was 0.13 during Q4 2019.
  • Over the past 5 years, Larimar Therapeutics' median Equity Ratio value was 0.79 (recorded in 2018), while the average stood at 0.76.
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 11741.96% in 2019, then skyrocketed by 3971.82% in 2020.
  • Quarter analysis of 5 years shows Larimar Therapeutics' Equity Ratio stood at 0.92 in 2016, then dropped by 19.84% to 0.74 in 2017, then grew by 3.33% to 0.77 in 2018, then crashed by 117.42% to 0.13 in 2019, then surged by 775.01% to 0.9 in 2020.
  • Its Equity Ratio stands at 0.9 for Q3 2020, versus 0.9 for Q2 2020 and 0.69 for Q1 2020.